Alerts will be sent to your verified email
Verify EmailSHIVALIK
|
Shivalik Rasayan
|
Medicamen Biotech
|
Jenburkt Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Chemicals
|
|||
|
Capacity Utilization - Dimethoate
|
95.0 % | n/a | n/a |
|
Realization/Tonne - Dimethoate
|
299080.92 Rs/MT | n/a | n/a |
|
Realization/Tonne - Sodium hydrosulfide
|
4487.46 Rs/MT | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
6.54 % | 6.92 % | 18.49 % |
|
5yr average Equity Multiplier
|
1.82 | 1.44 | 1.17 |
|
5yr Average Asset Turnover Ratio
|
0.44 | 0.55 | 0.88 |
|
5yr Avg Net Profit Margin
|
7.94 % | 8.69 % | 18.1 % |
|
Price to Book
|
0.85 | 1.74 | 2.48 |
|
P/E
|
35.27 | 44.66 | 13.71 |
|
5yr Avg Cash Conversion Cycle
|
100.7 Days | 49.75 Days | -32.02 Days |
|
Inventory Days
|
80.64 Days | 84.58 Days | 24.72 Days |
|
Days Receivable
|
107.04 Days | 139.4 Days | 48.38 Days |
|
Days Payable
|
166.18 Days | 264.75 Days | 82.6 Days |
|
5yr Average Interest Coverage Ratio
|
8.55 | 7.03 | 87.2 |
|
5yr Avg ROCE
|
8.54 % | 10.34 % | 24.44 % |
|
5yr Avg Operating Profit Margin
|
17.6 % | 15.51 % | 22.46 % |
|
5 yr average Debt to Equity
|
0.2 | 0.15 | 0.02 |
|
5yr CAGR Net Profit
|
-1.04 % | -11.57 % | 14.21 % |
|
5yr Average Return on Assets
|
3.57 % | 4.73 % | 15.8 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
47.37 % | 40.46 % | 46.65 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-2.95 % | -2.75 % | 0.68 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Shivalik Rasayan
|
Medicamen Biotech
|
Jenburkt Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|